J. C. Bendell

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

Serena Di Cosimo, J. C. Bendell, Andrés Cervantes et al. · Journal of Clinical Oncology · 2010 · 67 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

José Baselga, Maja J. De Jonge, Jordi Rodón et al. · Journal of Clinical Oncology · 2010 · 53 citations

Medicine, Oncology, Pharmacology +13

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

Geoffrey I. Shapiro, P. LoRusso, E. L. Kwak et al. · Journal of Clinical Oncology · 2011 · 44 citations

Medicine, Oncology, Pharmacology +16

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

Natalie R. Dickson, Suzanne F. Jones, H. A. Burris et al. · Journal of Clinical Oncology · 2011 · 34 citations

Medicine, Oncology, Pharmacology +7

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

Alan L. Ho, J. C. Bendell, J. M. Cleary et al. · Journal of Clinical Oncology · 2011 · 33 citations

Medicine, Oncology, Pharmacology +7